The trial will continue until @ confirmed primary outcome events have occurred , providing a power of @ % to yield an upper limit of the adjusted @ % CI for a hazard ratio of < @ with a one-sided of @ , assuming equal risks between placebo and empagliflozin ( both doses pooled ) .